Highnoon Laboratories Limited (PSX:HINOON)
905.20
-4.89 (-0.54%)
At close: Sep 17, 2026
Highnoon Laboratories Revenue
Highnoon Laboratories had revenue of 6.46B PKR in the quarter ending June 30, 2026, with 4.94% growth. This brings the company's revenue in the last twelve months to 28.50B, up 10.53% year-over-year. In the year 2025, Highnoon Laboratories had annual revenue of 27.71B with 12.44% growth.
Revenue (ttm)
28.50B
Revenue Growth
+10.53%
P/S Ratio
1.68
Revenue / Employee
11.12M
Employees
2,563
Market Cap
47.96B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.71B | 3.06B | 12.44% |
| Dec 31, 2024 | 24.64B | 4.87B | 24.66% |
| Dec 31, 2023 | 19.77B | 3.95B | 24.98% |
| Dec 31, 2022 | 15.82B | 2.82B | 21.65% |
| Dec 31, 2021 | 13.00B | 2.30B | 21.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Abbott Laboratories (Pakistan) | 77.02B |
| GlaxoSmithKline Pakistan | 67.12B |
| The Searle Company | 35.99B |
| AGP Limited | 27.70B |
| Ferozsons Laboratories | 22.68B |
| Citi Pharma | 13.84B |
| Macter International | 11.95B |
| Otsuka Pakistan | 4.11B |